Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Neurobiol ; 56(6): 4364-4380, 2019 Jun.
Article in English | MEDLINE | ID: mdl-30317434

ABSTRACT

Deep brain stimulation (DBS) of the medial forebrain bundle (MFB) displays a promising antidepressant effects in patients with treatment-refractory depression; however, a clear consensus on underlying mechanisms is still enigmatic. Herein, we investigated the effects of MFB-DBS on anhedonic-like behavior using the Froot Loops® consumption in a chronic unpredictable mild stress (CUS) model of depression, biochemical estimation of peripheral and central inflammatory cytokines, stress hormone, and brain-derived neurotrophic factor (BDNF). Seven days of MFB-DBS significantly reversed the 42-day CUS-generated anhedonic-like phenotype (p < 0.02) indicated by an increase in Froot Loops® consumption. Gross locomotor activity and body weight remained unaffected across the different groups. A dramatic augmentation of adrenocorticotropic hormone levels was seen in the plasma and cerebrospinal fluid (CSF) samples of CUS rats, which significantly reduced following MFB-DBS treatment. However, C-reactive protein levels were found to be unaffected. Interestingly, decreased levels of BDNF in the CUS animals were augmented in the plasma, CSF, and hippocampus following MFB-DBS, but remained unaltered in the nucleus accumbens (NAc). While multiplex assay revealed no change in the neuronal levels of inflammatory cytokines including IL-1α, IL-4, IL-10, IL-12, IL-13, and IL-17 in the neuroanatomical framework of the hippocampus and NAc, increased levels of IL-1ß, IL-2, IL-5, IL-6, IL-7, IL-18, TNF-α, and INF-γ were seen in these brain structures after CUS and were differentially modulated in the presence of MFB stimulation. Here, we show that there is dysregulation of BDNF and neuroimmune mediators in a stress-driven chronic depression model, and that chronic MFB-DBS has the potential to undo these aberrations.


Subject(s)
Anhedonia , Behavior, Animal , Brain-Derived Neurotrophic Factor/metabolism , Cytokines/metabolism , Deep Brain Stimulation , Depression/complications , Inflammation Mediators/metabolism , Medial Forebrain Bundle/pathology , Adrenocorticotropic Hormone/blood , Adrenocorticotropic Hormone/cerebrospinal fluid , Animals , Brain-Derived Neurotrophic Factor/blood , Brain-Derived Neurotrophic Factor/cerebrospinal fluid , C-Reactive Protein/cerebrospinal fluid , C-Reactive Protein/metabolism , Depression/blood , Depression/cerebrospinal fluid , Depression/physiopathology , Disease Models, Animal , Feeding Behavior , Hippocampus/metabolism , Male , Motor Activity , Nucleus Accumbens/metabolism , Rats, Wistar , Stress, Psychological/blood , Stress, Psychological/cerebrospinal fluid , Stress, Psychological/complications , Stress, Psychological/physiopathology
2.
Mol Neuropsychiatry ; 3(2): 108-124, 2017 11.
Article in English | MEDLINE | ID: mdl-29230399

ABSTRACT

Bipolar disorder (BD) is a major health problem. It causes significant morbidity and imposes a burden on the society. Available treatments help a substantial proportion of patients but are not beneficial for an estimated 40-50%. Thus, there is a great need to further our understanding the pathophysiology of BD to identify new therapeutic avenues. The preponderance of evidence pointed towards a role of protein kinase C (PKC) in BD. We reviewed the literature pertinent to the role of PKC in BD. We present recent advances from preclinical and clinical studies that further support the role of PKC. Moreover, we discuss the role of PKC on synaptogenesis and neuroplasticity in the context of BD. The recent development of animal models of BD, such as stimulant-treated and paradoxical sleep deprivation, and the ability to intervene pharmacologically provide further insights into the involvement of PKC in BD. In addition, the effect of PKC inhibitors, such as tamoxifen, in the resolution of manic symptoms in patients with BD further points in that direction. Furthermore, a wide variety of growth factors influence neurotransmission through several molecular pathways that involve downstream effects of PKC. Our current understanding identifies the PKC pathway as a potential therapeutic avenue for BD.

3.
Am J Physiol Heart Circ Physiol ; 308(5): H435-46, 2015 Mar 01.
Article in English | MEDLINE | ID: mdl-25539713

ABSTRACT

Sleep apnea is associated with hypertension. The mechanisms contributing to a sustained increase in mean arterial pressure (MAP) even during normoxic awake-state remain unknown. Rats exposed to chronic intermittent hypoxia for 7 days, a model of the hypoxemia associated with sleep apnea, exhibit sustained increases in MAP even during the normoxic dark phase. Activation of the renin-angiotensin system (RAS) has been implicated in chronic intermittent hypoxia (CIH) hypertension. Since the subfornical organ (SFO) serves as a primary target for the central actions of circulating ANG II, we tested the effects of ANG II type 1a receptor (AT1aR) knockdown in the SFO on the sustained increase in MAP in this CIH model. Adeno-associated virus carrying green fluorescent protein (GFP) and small-hairpin RNA against either AT1aR or a scrambled control sequence (SCM) was stereotaxically injected in the SFO of rats. After recovery, MAP, heart rate, respiratory rate, and activity were continuously recorded using radiotelemetry. In the normoxic groups, the recorded variables did not deviate from the baseline values. Both CIH groups exhibited significant increases in MAP during CIH exposures (P < 0.05). During the normoxic dark phase in the CIH groups, only the SCM-injected group exhibited a sustained increase in MAP (P < 0.05). The AT1aR-CIH group showed significant decreases in FosB/ΔFosB staining in the median preoptic nucleus and the paraventricular nuclei of the hypothalamus compared with the SCM-CIH group. Our data indicate that AT1aRs in the SFO are critical for the sustained elevation in MAP and increased FosB/ΔFosB expression in forebrain autonomic nuclei associated with CIH.


Subject(s)
Blood Pressure , Hypertension/metabolism , Hypoxia/metabolism , Receptor, Angiotensin, Type 1/metabolism , Sleep Apnea Syndromes/metabolism , Subfornical Organ/metabolism , Animals , Hypertension/etiology , Hypertension/physiopathology , Hypoxia/complications , Hypoxia/physiopathology , Male , Rats , Rats, Sprague-Dawley , Receptor, Angiotensin, Type 1/genetics , Sleep Apnea Syndromes/complications , Sleep Apnea Syndromes/physiopathology , Subfornical Organ/physiopathology
4.
Am J Physiol Regul Integr Comp Physiol ; 307(8): R945-55, 2014 Oct 15.
Article in English | MEDLINE | ID: mdl-25080500

ABSTRACT

Transient receptor potential vanilloid family type 4 (TRPV4) channels are expressed in central neuroendocrine neurons and have been shown to be polymodal in other systems. We previously reported that in the rodent, a model of dilutional hyponatremia associated with hepatic cirrhosis, TRPV4 expression is increased in lipid rafts from the hypothalamus and that this effect may be angiotensin dependent. In this study, we utilized the immortalized neuroendocrine rat hypothalamic 4B cell line to more directly test the effects of angiotensin II (ANG II) on TRPV4 expression and function. Our results demonstrate the expression of corticotropin-releasing factor (CRF) transcripts, for sex-determining region Y (SRY) (male genotype), arginine vasopressin (AVP), TRPV4, and ANG II type 1a and 1b receptor in 4B cells. After a 1-h incubation in ANG II (100 nM), 4B cells showed increased TRPV4 abundance in the plasma membrane fraction, and this effect was prevented by the ANG II type 1 receptor antagonist losartan (1 µM) and by a Src kinase inhibitor PP2 (10 µM). Ratiometric calcium imaging experiments demonstrated that ANG II incubation potentiated TRPV4 agonist (GSK 1016790A, 20 nM)-induced calcium influx (control 18.4 ± 2.8% n = 5 and ANG II 80.5 ± 2.4% n = 5). This ANG II-induced increase in calcium influx was also blocked by 1 µM losartan and 10 µM PP2 (losartan 26.4 ± 3.8% n = 5 and PP2 19.7 ± 3.9% n = 5). Our data suggests that ANG II can increase TRPV4 channel membrane expression in 4B cells through its action on AT1R involving a Src kinase pathway.


Subject(s)
Angiotensin II/pharmacology , Hypothalamus/drug effects , Hypothalamus/metabolism , TRPV Cation Channels/metabolism , Animals , Calcium/metabolism , Cell Line , Cells, Cultured , Hypothalamus/pathology , Leucine/analogs & derivatives , Leucine/pharmacology , Membrane Microdomains/drug effects , Membrane Microdomains/metabolism , Membrane Microdomains/pathology , Morpholines/pharmacology , Protein Transport/drug effects , Pyrroles/pharmacology , Rats , Receptor, Angiotensin, Type 1/metabolism , Signal Transduction/physiology , Sulfonamides/pharmacology , TRPV Cation Channels/agonists , TRPV Cation Channels/antagonists & inhibitors , src-Family Kinases/metabolism
5.
Cell Biochem Biophys ; 70(2): 923-32, 2014 Nov.
Article in English | MEDLINE | ID: mdl-24839116

ABSTRACT

Presenilin-1 (PS1) protein acts as passive ER Ca(2+) leak channels that facilitate passive Ca(2+) leak across ER membrane. Mutations in the gene encoding PS1 protein cause neurodegeneration in the brains of patients with familial Alzheimer's disease (FAD). FADPS1 mutations abrogate the function of ER Ca(2+) leak channel activity in human neuroblastoma SK-N-SH cells in vitro (Das et al., J Neurochem 122(3):487-500, 2012) and in mouse embryonic fibroblasts. Consequently, genetic deletion or mutations of the PS1 gene cause calcium (Ca(2+)) signaling abnormalities leading to neurodegeneration in FAD patients. By analogy with other known ion channels it has been proposed that the functional PS1 channels in ER may be multimers of several PS1 subunits. To test this hypothesis, we conjugated the human PS1 protein with an NH2-terminal YFP-tag and a COOH-terminal CFP-tag. As expected YFP-PS1, and PS1-CFP were found to be expressed on the plasma membranes by TIRF microscopy, and both these fusion proteins increased ER Ca(2+) leak channel activity similar to PS1 (WT) in SK-N-SH cells, as determined by functional calcium imaging. PS1-CFP was either expressed alone or together with YFP-PS1 into SK-N-SH cell line and the interaction between YFP-PS1 and PS1-CFP was determined by Förster resonance energy transfer analysis. Our results suggest interaction between YFP-PS1 and PS1-CFP confirming the presence of a dimeric or multimeric form of PS1 in SK-N-SH cells. Lateral diffusion of PS1-CFP and YFP-PS1 in the plasma membrane of SK-N-SH cells was measured in the absence or in the presence of glycerol by fluorescence correlation spectroscopy to show that both COOH-terminal and NH2-terminal of human PS1 are located on the cytoplasmic side of the plasma membrane. Therefore, we conclude that both COOH-terminal and NH2-terminal of human PS1 may also be oriented on the cytosolic side of ER membrane.


Subject(s)
Cell Membrane/metabolism , Fluorescence Resonance Energy Transfer , Presenilin-1/metabolism , Cell Line, Tumor , Cytoplasm/metabolism , Diffusion , Humans , Presenilin-1/chemistry , Protein Transport
7.
Am J Physiol Regul Integr Comp Physiol ; 305(9): R1051-8, 2013 Nov 01.
Article in English | MEDLINE | ID: mdl-24026072

ABSTRACT

Chronic intermittent hypoxia (CIH) increases mean arterial pressure (MAP) and FosB/ΔFosB staining in central autonomic nuclei. To test the role of the brain renin-angiotensin system (RAS) in CIH hypertension, rats were implanted with intracerebroventricular (icv) cannulae delivering losartan (1 µg/h) or vehicle (VEH) via miniosmotic pumps and telemetry devices for arterial pressure recording. A third group was given the same dose of losartan subcutaneously (sc). Two groups of losartan-treated rats served as normoxic controls. Rats were exposed to CIH or normoxia for 7 days and then euthanized for immunohistochemistry. Intracerebroventricular losartan attenuated CIH-induced increases in arterial pressure during CIH exposure (0800-1600 during the light phase) on days 1, 6, and 7 and each day during the normoxic dark phase. FosB/ΔFosB staining in the organum vasculosum of the lamina terminalis (OVLT), median preoptic nucleus (MnPO), paraventricular nucleus of the hypothalamus (PVN), the rostral ventrolateral medulla (RVLM), and the nucleus of the solitary tract (NTS) was decreased in icv losartan-treated rats. Subcutaneous losartan also reduced CIH hypertension during the last 2 days of CIH and produced bradycardia prior to the effect on blood pressure. Following sc losartan, FosB/ΔFosB staining was reduced only in the OVLT, MnPO, PVN, and NTS. These data indicate that the central and peripheral RAS contribute to CIH-induced hypertension and transcriptional activation of autonomic nuclei and that the contribution of the central RAS is greater during the normoxic dark phase of CIH hypertension.


Subject(s)
Angiotensin II Type 1 Receptor Blockers/administration & dosage , Arterial Pressure/drug effects , Autonomic Nervous System/drug effects , Brain/drug effects , Hypertension/prevention & control , Hypoxia/drug therapy , Losartan/administration & dosage , Proto-Oncogene Proteins c-fos/metabolism , Renin-Angiotensin System/drug effects , Animals , Autonomic Nervous System/metabolism , Autonomic Nervous System/physiopathology , Brain/metabolism , Brain/physiopathology , Chronic Disease , Circadian Rhythm , Disease Models, Animal , Down-Regulation , Hypertension/etiology , Hypertension/genetics , Hypertension/metabolism , Hypertension/physiopathology , Hypoxia/complications , Hypoxia/genetics , Hypoxia/metabolism , Hypoxia/physiopathology , Infusions, Intraventricular , Infusions, Subcutaneous , Male , Photoperiod , Rats , Rats, Sprague-Dawley , Time Factors , Transcriptional Activation
9.
Exp Physiol ; 98(2): 451-61, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23024369

ABSTRACT

We tested the hypothesis that pharmacological blockade of α(1)-adrenoreceptors (by prazosin), at rest and during steady-state dynamic exercise, would impair cerebral autoregulation and result in cerebral vasodilatation in healthy humans. In 10 subjects, beat-to-beat mean arterial pressure and mean middle cerebral artery blood velocity were determined at rest and during low (Ex90) and moderate workload (Ex130) on an upright bicycle ergometer without and with prazosin. Plasma noradrenaline concentrations increased significantly from rest to Ex130 during control conditions (from 1.8 ± 0.2 to 3.2 ± 0.3 pmol (ml plasma)(-1)). In the control conditions, the transfer function gain between mean arterial pressure and mean middle cerebral artery blood velocity in the low-frequency range was decreased at Ex90 (P = 0.035) and Ex130 (P = 0.027) from rest. A significant increase in critical closing pressure (CCP) was also observed in the control conditions from rest to Ex90 to Ex130 (from 18 ± 3 to 24 ± 4 to 31 ± 4 mmHg). An average of 74 ± 2% blockade of blood pressure response was achieved with oral prazosin. Following blockade, plasma noradrenaline concentrations further increased at rest and during Ex130 from the control value (from 2.6 ± 0.3 to 4.4 ± 0.5 pmol (ml plasma)(-1)). Prazosin also resulted in an increase in low-frequency gain (P < 0.003) compared with the control conditions. Prazosin blockade abolished the increases in CCP during Ex130 and increased the cerebrovascular conductance index (P = 0.018). These data indicate that in the control conditions a strengthening of cerebral autoregulation occurred with moderate dynamic exercise that is associated with an increase in CCP as a result of the exercise-mediated augmentation of sympathetic activity. Given that α(1)-adrenergic receptor blockade attenuated the increase in dynamic cerebral autoregulation and CCP, we conclude that increases in sympathetic activity have a role in establishing cerebral vascular tone in humans.


Subject(s)
Adrenergic Fibers/metabolism , Cerebrovascular Circulation , Exercise , Middle Cerebral Artery/innervation , Receptors, Adrenergic, alpha-1/metabolism , Rest , Administration, Oral , Adrenergic Fibers/drug effects , Adrenergic alpha-1 Receptor Agonists/administration & dosage , Adrenergic alpha-1 Receptor Antagonists/administration & dosage , Adult , Analysis of Variance , Arterial Pressure , Bicycling , Blood Flow Velocity , Cerebrovascular Circulation/drug effects , Female , Homeostasis , Humans , Injections, Intravenous , Male , Middle Cerebral Artery/drug effects , Norepinephrine/blood , Phenylephrine/administration & dosage , Prazosin/administration & dosage , Receptors, Adrenergic, alpha-1/drug effects , Regional Blood Flow , Time Factors , Vasodilation
SELECTION OF CITATIONS
SEARCH DETAIL
...